Guidelines for the treatment of bacterial vaginosis: focus on tinidazole

• Main Authors: Laura J Dickey, Michael D Nailor, Jack D Sobel
• Format: Article
• Language: English
• Published: Dove Medical Press 2009-06-01
• Series: Therapeutics and Clinical Risk Management
• Online Access: http://www.dovepress.com/guidelines-for-the-treatment-of-bacterial-vaginosis-focus-on-tinidazol-a3279
• ISSN: 1176-6336; 1178-203X

Laura J Dickey1, Michael D Nailor2,3, Jack D Sobel41Department of Pharmacy Services, Detroit Receiving Hospital, Detroit, MI, USA; 2University of Connecticut, School of Pharmacy, Storrs, CT, USA; 3Hartford Hospital, Department of Pharmacy, Hartford, CT, USA; 4Wayne State University, School of Medicine, Detroit, MI, USAAbstract: Bacterial vaginosis (BV) is a complex vaginal infection most commonly associated with women of child-bearing age. Risk factors for BV are numerous. There are currently multiple clinical and laboratory tests for diagnosis of BV, including the most commonly used diagnostic methods: Amsel’s criteria or Nugent’s Gram stain scale. The mainstay of BV therapy is metronidazole, but tinidazole as well as a few other agents have also been used successfully. Tinidazole is the second nitroimidazole antiprotozoal agent and a structural derivative of metronidazole. With a favorable pharmacokinetic profile and reduced side effects, tinidazole is an alternative agent for BV treatment. There are minimal head-to-head comparative data to establish tinidazole’s superiority to metronidazole or other therapeutic agents. Available data suggest tinidazole has a role in special populations particularly for refractory or relapsing BV.Keywords: bacterial vaginosis, vaginosis, tinidazole, Gardnerella